References
- Novak R, Shlaes DM. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs. 2010;11:182–191.
- Woodward K. Toxicological effects of veterinary medicinal products in humans. Vol. 1, Cambridge, UK: The Royal Society of Chemistry; 2013.
- Novak R. Are pleuromutilin antibiotics finally fit for human use? Ann N Y Acad Sci. 2011;1241:71–81.
- EMA Committee for veterinary medicinal products – Tiamulin Summary report [cited 2019 Jan 29]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500015563.pdf
- Tiamulin. TOXNET – Toxicology Data Network [cited 2019 Jan 29]; Available from: https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@DOCNO+7026
- Entemulin. [cited 2019 May 2]; Available from: https://www.krka.biz/media/products/si/vet/exp_pdf/2019/Entemulin_SmPC.pdf
- Nakajyo S, Hara Y, Hirano S, et al. Inhibitory effects of tiamulin on contractile and electrical responses in isolated thoracic aorta and cardiac muscle of guinea-pigs. J Pharm Pharmacol. 1992;44:731–736.
- Somberg JC. Calcium channel blockers that prolong the QT interval. Am Heart J. 1985;109:416–421.
- Tang YZ, Liu YH, Chen JX. Pleuromutilin and its derivatives-the lead compounds for novel antibiotics. Mini Rev Med Chem. 2012;12:53–61.
- Hong W, Lee YS, Park CW, et al. An open label, multi-center, non-interventional post-marketing surveillance to monitor the safety and efficacy of ALTARGO® (retapamulin) administered in Korean patients according to the prescribing information. Ann Dermatol. 2018;30:441–450.
- Nabriva Therapeutics Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia [cited 2019 Jan 1]; Available from: https://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-announces-positive-topline-results-pivotal